

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant: Axel ULLRICH et al.  
Title: TREATMENT OF DIABETES MELLITUS AND  
INSULIN RECEPTOR SIGNAL TRANSDUCTION  
Appl. No.: Unassigned  
Filing Date: March 19, 2001  
Examiner: Unassigned  
Art Unit: Unassigned



**INFORMATION DISCLOSURE STATEMENT**  
**UNDER 37 CFR §1.56**

Commissioner for Patents  
Washington, D.C. 20231

Sir:

Applicants submit herewith on Form PTO-1449 a listing of the documents cited by or submitted to the U.S. PTO in parent application Serial No. 09/232,073, filed January 15, 1999. As provided in 37 CFR §1.98(d), copies of the documents are not being provided since they were previously submitted to the United States Patent & Trademark Office in the above-identified parent application.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or that such document is considered material to patentability as defined in 37 CFR §1.56(b). Applicants do not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a *prima facie* art reference against the claims of the present application.

**TIMING OF THE DISCLOSURE**


The listed documents are being submitted in compliance with 37 CFR §1.97(b), within three (3) months of the filing date of the application.

**RELEVANCE OF EACH DOCUMENT**

Applicants respectfully request that any listed document be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO-1449 be returned in accordance with MPEP §609.

Respectfully submitted,

By

  
Beth A. Burrous  
Attorney for Applicant  
Registration No. 35,087

Date March 19, 2001

FOLEY & LARDNER  
Washington Harbour  
3000 K Street, N.W., Suite 500  
Washington, D.C. 20007-5109  
Telephone: (202) 672-5475  
Facsimile: (202) 672-5399

Form PTO-1449  
(MODIFIED)U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.  
038602/1126SERIAL NO.  
Unassigned

## INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

APPLICANT

Axel ULLRICH et al.

FILING DATE

March 19, 2001

GROUP ART UNIT

Unassigned

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE

U.S. PTO  
09/10/01  
03/19/01

## FOREIGN PATENT DOCUMENTS

	REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION	
							YES	NO

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

983	A1	I George Fantus et al., "Pervanidate[Peroxide(s) of Vanadate] Mimics Insulin Action in Rat Adipocytes via Activation of the Insulin Receptor Tyrosine Kinase.", Biochemistry (28), pp. 8864-8871, 1989, Protein and Polypeptide Hormone Laboratory, Strathcona Medical Building, Royal Victoria Hospital and McGill University, Montreal, Quebec, Canada H3A 2B2
	A2	Li et al., "Phenylarsine Oxide and Vanadate: Apparent Paradox of Inhibition of Protein Phosphotyrosine Phosphatases in Rat Adipocytes.", Biochimica et Biophysica Acta 1312, pp. 223-230

EXAMINER

DATE CONSIDERED

- \* EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include any copy of this form with next communication to applicant.